Efficacy, Safety and Pharmacokinetics of a Novel Subcutaneous Immunoglobulin, Evogam®, in Primary Immunodeficiency

Empson, Marianne; Tang, Mimi L.K.; Pearce, L. K.; Rozen, Leon; Gold, Michael; Katelaris, Constance H.; Langton, David; Smart, Joanne; Smith, William B.; Steele, Richard; Ziegler, John B.; Maher, Darryl

doi:10.1007/s10875-011-9641-4

Cited by 6 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although IVIG replacement therapy has been used for many years, there have been more than 25 years of accumulated experience with SCIG therapy in Europe, especially in the Nordic countries. SCIG is now widely available in Europe, the United States and a steadily growing number of other countries [24,[32][33][34][35][36][37].…”

Section: Routes Of Administration: Ivig and Scig For Individualized Tmentioning

confidence: 99%

“…2) is associated with a substantially reduced incidence of systemic and severe AEs [38]. In addition, the near steady-state serum IgG levels achieved with weekly or more frequent SCIG administration confer comparable protection against infections [5,11,12,34,[42][43][44]. In contrast, recent pooled analyses showed that the incidence of infection increases as the IgG level falls towards the end of each 3-or 4-week IVIG dosing cycle [45].…”

Section: Routes Of Administration: Ivig and Scig For Individualized Tmentioning

confidence: 99%

See 1 more Smart Citation

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

Jolles

Orange

Gardulf

et al. 2015

Clinical and Experimental Immunology

135

130

View full text Add to dashboard Cite

SummaryPrimary antibody deficiencies require lifelong replacement therapy with immunoglobulin (Ig)G to reduce the incidence and severity of infections. Both subcutaneous and intravenous routes of administering IgG can be effective and well tolerated. Treatment regimens can be individualized to provide optimal medical and quality-of-life outcomes in infants, children, adults and elderly people. Frequency, dose, route of administration, home or infusion-centre administration, and the use of self-or health-professionaladministered infusion can be tailored to suit individual patient needs and circumstances. Patient education is needed to understand the disease and the importance of continuous therapy. Both the subcutaneous and intravenous routes have advantages and disadvantages, which should be considered in selecting each patient's treatment regimen. The subcutaneous route is attractive to many patients because of a reduced incidence of systemic adverse events, flexibility in scheduling and its comparative ease of administration, at home or in a clinic. Self-infusion regimens, however, require independence and self-reliance, good compliance on the part of the patient/parent and the confidence of the physician and the nurse. Intravenous administration in a clinic setting may be more appropriate in patients with reduced manual dexterity, reluctance to self-administer or a lack of self-reliance, and intravenous administration at home for those with good venous access who prefer less frequent treatments. Both therapy approaches have been demonstrated to provide protection from infections and improve health-related quality of life. Data supporting current options in IgG replacement are presented, and considerations in choosing between the two routes of therapy are discussed.

show abstract

Section: Routes Of Administration: Ivig and Scig For Individualized Tmentioning

confidence: 99%

Section: Routes Of Administration: Ivig and Scig For Individualized Tmentioning

confidence: 99%

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

Jolles

Orange

Gardulf

et al. 2015

Clinical and Experimental Immunology

135

130

View full text Add to dashboard Cite

show abstract

Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency

Tortorici

Lawo

Weide³

et al. 2019

International Immunopharmacology

View full text Add to dashboard Cite

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies

Shabaninejad

Asgharzadeh

Rezapour

et al. 2017

Med. J. Islam. Republic Iran

View full text Add to dashboard Cite

Background: Economic evaluation of subcutaneous immunoglobulin therapy (SCIG) is important, and it has recently been used for treatment of patients with primary immunodeficiency (PID) diseases, and can improve allocation of resources in health care systems. The present research aimed at providing an economic assessment of SCIG and IVIG (intravenous immunoglobulin therapy) administration in Iran. Methods: Data related to clinical effectiveness were obtained from a meta-analysis. Economic analysis was performed taking into account the perspective of health care providers. Incremental cost-effectiveness ratio (ICER) was applied for economic evaluation of the 2 methods, and GDP per capita was considered as a threshold. Results: The results of meta-analysis suggested a higher effectiveness of SCIG compared to IVIG in serum immunoglobulin (Ig) levels (SMD= 0.336) and adverse effects (OR= 0.497), while the cost of IVIG was higher than SCIG ($1370 vs. $121). The ICER obtained in this paper ($2939 for adverse effects and $4348 for serum Ig level) was less than the GDP per capita in Iran ($4,916.10), and thus SCIG is a more cost-effective therapy for PID patients. Conclusion: Switching from IVIG to SCIG is cost-effective for PID patients and is approved by the health care providers’ points of view in this study.

show abstract

Efficacy, Safety and Pharmacokinetics of a Novel Subcutaneous Immunoglobulin, Evogam®, in Primary Immunodeficiency

Cited by 6 publications

References 15 publications

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease

Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies

Contact Info

Product

Resources

About